Arthneeti

Walpar Nutritions Q2 FY27 Share Price & Earnings Call Analysis

₹25.00-4.21% today
Market cap
₹23 Cr
P/E
9.51
ROE
13.93%
PEG
0.16
Price to sales
0.30
Debt to equity
0.89
52W high / low
₹53.3 / ₹37.7
Sales growth (5Y)
66.97%
EBITDA margin
8.45%
Net profit margin
3.81%
Promoter holding
68.99%
Sales (last year)
₹79 Cr

Incorporated in 2009, Walpar Nutrition Ltd develops and manufactures various pharmaceutical products.[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Walpar Nutrition rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹18,347 Cr—
440%+Flat₹8,418 Cr32.3
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Walpar Nutrition.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Walpar Nutrition

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Walpar Nutrition

Shareholding breakup across reporting periods.

Sep 2021Mar 2022Sep 2022Mar 2023May 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026Sep 2026
Promoters +71.02%71.02%70.58%70.54%71.46%71.46%71.23%68.44%68.52%68.61%68.82%68.99%
Public +28.98%28.98%29.42%29.46%28.54%28.54%28.77%31.56%31.48%31.39%31.18%31.01%
No. of Shareholders496460291270258233226335333345327336

Financials of Walpar Nutrition

Quarterly Results

Quarter-by-quarter operating performance

No quarterly results data available for this company yet.

Financials of Walpar Nutrition

Profit & Loss

Annual income statement trend

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +6.0726.7635.1462.5271.7678.7783.22
Sales growth+340.86%+31.32%+77.92%+14.78%+9.77%+9.89%
Expenses +5.6125.7431.6557.7766.0472.1175.31
Operating Profit0.461.023.494.755.726.667.91
OPM %7.58%3.81%9.93%7.60%7.97%8.45%9.50%
Other Income +0.000.020.320.220.270.260.53
Interest0.180.480.790.670.290.801.11
Depreciation0.120.281.911.811.822.022.31
Profit before tax0.160.281.112.493.884.105.02
Tax %6.25%-32.14%27.03%22.09%27.84%21.71%
Net Profit +0.150.360.811.942.793.003.24
EPS in Rs0.220.420.651.682.472.632.59
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%

Financials of Walpar Nutrition

Balance Sheet

Capital structure and asset base

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital3.344.544.544.709.399.399.39
Reserves1.446.457.179.497.179.5110.98
Borrowings +7.497.2510.308.307.8516.7716.82
Other Liabilities +5.739.8512.2914.6722.9830.4028.46
Total Liabilities18.0028.0934.3037.1647.3966.0765.65
Fixed Assets +1.702.0110.1310.2010.6512.2114.91
CWIP1.224.480.020.020.030.050.06
Investments0.000.490.021.881.882.882.90
Other Assets +15.0821.1124.1325.0634.8350.9347.78
Total Assets18.0028.0934.3037.1647.3966.0765.65

Financials of Walpar Nutrition

Cash Flows

Operating, investing and financing cash movement

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-0.31-1.081.105.354.061.83
Cash from Investing Activity +-2.02-6.14-3.44-3.61-2.30-6.57
Cash from Financing Activity +2.956.712.42-1.77-0.688.08
Net Cash Flow0.62-0.510.07-0.031.083.34
Free Cash Flow-2.17-4.92-4.143.481.78-1.76
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit-67%-99%34%116%82%41%

Financials of Walpar Nutrition

Ratios

Working capital efficiency and return ratios

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days430.54124.26129.6378.46107.73108.66
Inventory Days369.26103.22128.7367.1567.8593.74
Days Payable455.40135.07143.8872.94108.50136.31
Cash Conversion Cycle344.4192.41114.4872.6767.0766.09
Working Capital Days316.2961.6587.8743.5542.1740.68
ROCE %4.85%8.78%12.75%16.08%14.84%

Continue your research

What Walpar Nutrition's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Divis Laboratories (Q2 FY27)

    Consolidated total income: ₹3770 crores . Key results statement takeaways from Divis Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sec

  • Infinium Pharma (Q2 FY27)

    3,940.98 Lacs (about 54.3% increase) . Key results statement takeaways from Infinium Pharmachem Ltd's Q2 FY27 results statement — and how it ranks against secto

  • Kilitch Drugs (Q2 FY27)

    14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • NGL Fine Chem (Q2 FY27)

    Consolidated: ₹15,870.73 lakhs . Key results statement takeaways from NGL Fine Chem Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals